The Food and Drug Administration has given full approval to the Alzheimer’s drug Leqembi, and Medicare said it would cover much of its high cost, laying the foundation for widespread use of a medication that can modestly slow cognitive decline in the early stages of the disease but also carries significant safety risks. Duke University Dr. Andy Liu, a neurologist at Duke University, joined Nate Saunders to discuss the impact the Alzheimer's drug could have.